Why Taiwan Liposome's Stock Is Trading Higher Today

Taiwan Liposome TLC shares are trading higher on Monday.

The company announced the results of its TLCS590 Phase 2 Trial for its Postsurgical pain management demonstrated greater reduction in pain.

Cantor Fitzgerald also maintained its Overweight on the company and raised its price target from $10 to $12 per share.

Taiwan Liposome is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products based on its proprietary drug delivery technologies. The company offers products in therapeutic areas, such as oncology, PAD, ophthalmology, fungal infection, arthritis, and anesthetic indications

Taiwan Liposome shares were trading up 8.82% at $5.34 at time of publication on Monday. The stock has a 52-week high of $8.54 and a 52-week low of $2.48.

Related Links:

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Moderna, Lonza Strike Deal To Manufacture Up To 1 Billion Doses Of Coronavirus Vaccine Candidate Annually